## Which is the Right Assessment Instrument? (What Have We Learned from EOSQ-24)

### Michael G. Vitale, MD MPH

Ana Lucia Professor of Orthopedic Surgery Columbia University College of Physicians and Surgeons

Co-Director Division of Pediatric Orthopaedic Surgery Chief of Pediatric Spine and Scoliosis Service Medical Director, MSCH Initiative to Make Care Better New York-Presbyterian Morgan Stanley Children's Hospital

## -Disclosures-

#### Michael G. Vitale, MD MPH

Disclosure: I DO have a financial relationship with a commercial interest.

Royalties: Biomet

Consultant: Stryker, Biomet, MSD

Research Support: CSSG, SRS, OREF, POSNA

Travel Support: CSSG, FoxPSDSG

BOD: IPOS, CSSG, POSNA

Funded by the CSSG



#### **EOS Research Platform**

Development of a Research Infrastructure
Via Six Parallel Efforts

**Endpoints** 

Development/Validation of a Disease-Specific QoL Measure

Equipoise

Identifying Clinical Equipoise in the Field of EOS

**Classification-EOS** 

Development / Validation of Classification for EOS

Standardizing Complications

Standardize Way We Define and Report Complications

Predicting Complications

**EOS Risk Severity Score** 

**Clinical Trials** 

Proximal Anchors: Rib vs Spine – Retrospective and Prospective



# Types of Health Outcomes Measures



#### Clinical

- Labs
- Clinical Events
- Physician Assessments



#### **Economic**

- Direct and Indirect costs
- Cost-utility
- Costeffectiveness
- Cost-benefit

#### Patient-Based

- Symptom reports
- Health status
- Quality of Life
- Patient Satisfaction





### Generic vs. Disease-specific?

- Generic health instruments address larger health constructs and hence their causal links to specific treatment events may be more difficult to detect
  - Eg. CHQ, SF-36
- Disease-specific instrument will vary with the condition being treated, and hence are typically more sensitive to treatment effects
  - Clubfoot DSI (Roye, Vitale, et al, 2001)
  - ACEND (Matsumoto, Vitale, et al, 2011)
  - EOSQ (Corona, Vitale, et al, 2011)



### **Patient-Based Outcomes in EOS**

- Difficult to measure
  - Heterogenous population
  - Significant comorbidities
  - Age is variable
  - Natural History can be subclinical in childhood






### Multicenter VEPTR Study--CHQ

**QOL** in Pediatrics

Vitale et al. J Pediatr Orthop 2008; 28:239-243



- CHQ scores are lower than those with:
  - Asthma
  - Juvenile Rheumatoid Arthritis
  - Heart transplant

- Concerns about responsiveness to clinical change after intervention
  - Instrument not sensitive?
  - Intervention not effective?
- CHQ did not adequately reflect issues *unique* to the EOS population



# Early Onset Scoliosis Questionnaire (EOSQ)

#### **Purpose:**

• To develop a disease specific instrument which reflects issues of importance to patients with EOS and caretakers, and is responsive to clinical changes after treatments





**Literature Review** 

**Existing Instruments** 

**Expert Opinion** 

Semi-structured Interview Topic Items



**Parent interviews** 



Mater List of 75 Items

Content Validity

Construct Validity

**EOSQ** 



### **Master List of 75 Items**

## 75 items in 11 Domains were produced:

1. General Health	6. Daily Living
2. Pain Discomfort	7. Pain
3. Pulmonary Function	8. Fatigue, Child Emotion
4. Physical Function	9. Surgical Burden
5. Transfer	10. Parental Burden
	11. Financial Burden





### **Item Statistics**

#### E.g. Activity of Daily Living Domain

Item #	Floor	Ceiling	Mean	Normal Distribution	Item Reliability	Relevance & Clarity
33	19.2%	38.5%	3.31		.667 (vs. 34) .871 (vs. 35) .845 (vs. 36)	3.64
					.579 (vs. 37)	
34	3.7%	81.5%	4.56		.667 (vs. 33) .795 (vs. 35)	3.35
					.677 (vs. 36) .767 (vs. 37)	8
35	3.7%	70.4%	4.41		.871 (vs. 33) .795 (vs. 34) .929 (vs. 36) .538 (vs. 37)	4.00
36	26.7%	53.3%	3.60		.845 (vs. 33) .677 (vs. 34) .929(vs. 35) .388 (vs. 37)	3.87
37	3.6%	82.1%	4.61		.579 (vs. 33) .767 (vs. 34) .538 (vs. 35) .388 (vs. 36)	4.30

#### Measuring Quality of Life in Children With Early Onset Scoliosis: Development and Initial Validation of the Early Onset Scoliosis Questionnaire

Jacqueline Corona, MD,\*† Hiroko Matsumoto, MA,\*†
David P. Roye, Jr, MD,\*† and Michael G. Vitale, MD, MPH\*†

## Caregiver form with 24 items, 3 domains, 11 sub-domains Raw scores transformed to 0-100 scale scores

Domain	Sub-Domain		
Patient Quality of	General Health		
Life	Pain/Discomfort		
	Pulmonary Function		
	Physical Function/Transfer		
	Daily Living		
	Fatigue/Energy Level		
	Emotion		
Family Burden	Parental Burden		
	Financial Burden		
Satisfaction	Patient Satisfaction		
	Parent Satisfaction		



### **EOSQ Project Overview**

Phase 1 – Development of the EOSQ COMPLETE

Phase 2 - Initial Validation and Responsiveness COMPLETE

Phase 3 – Collection of Age-Based Normative Data COMPLETE

Phase 4 - Prospective Validation, Reliability COMPLETE



### Phase 5 – Cross Translation Translation of the EOSQ

**English** PUBLISHED

Spanish Dr. Farrington – PUBLISHED

Hispanic Spanish Dr. Flynn & Dr. Ramirez – PUBLISHED

Turkish Dr. Yazici - PUBLISHED

Danish Dr. Bünger - translation underway

Japanese Dr. Kawakami - translation underway

Mandarin Chinese Dr. Xu - translation underway

French Translation underway at McGill Univ.



# Validation, Reliability and Responsiveness

Validity: Does it measure what it says it measures?

- Content
- Construct
- Criterion

Reliability: Does it measure consistently?

- internally consistent
- test- retest
  - (Cronbachs Alpha)

Responsiveness: in an expected manner to clinical change

### **Validity**

Cohort	Domain	Pre-op	Age Norm
Idiopathic	Physical <b>94</b> Function		97
	Fatigue	88	92
	Emotion	81	95

## Idiopathic pts with EOS have small differences in QOl c/w Norms



### **Validity**

Cohort	Domain	Pre-op	Age Norm
	Pulmonary Function	58	98
	Transfer	39	99
SMA	Fatigue	41	93
	Emotion	53	94
	Parental Burden	40	93

Patients with Other Comorbidities have much more significant decreases in QOL





## Multiple EOSQ-24 Domain Scores Positively Correlated With % Predicted Values of FVC and FEV1

	Percent FEV1 Predicted	Percent FVC Predicted	Percent FEV1/FVC Predicted		
<b>EOSQ Domain</b>	r value	r value	r value		
General Health	0.78*	0.78*	-0.05		
Pain/Discomfort	0.68*	0.58	0.27		
<b>Pulmonary Function</b>	0.72*	0.61	0.34		
Transfer	0.36	0.39	-0.10		
Physical Function	0.69	0.74*	-0.16		
Daily Living	0.69*	0.71*	-0.11		
Faitgue/Energy Level	0.78**	0.80**	-0.03		
Emotion	0.82**	0.79*	0.05		
Parental Burden	0.56	0.45	0.16		
Financial Burden	0.08	0.14	-0.32		
Child Satisfaction	0.47	0.43	0.25		
Parental Satisfation	0.28	0.22	0.37		
N = 10	* = p < .05, ** = p < 0.01				

Vitale MD MP

### Complications worsen Pain; Without complication, Pulmonary Function and Parental Burden Improve

Cohort	Domain	Preop	Postop 1 <sup>st</sup> /2nd	Р	Age Norm
With Intra-op Complication	Pain	72	59	0.092	95
No Post-op	Pulmonary Function	83	88	0.075	97
Complication	Parental Burden	61	66	0.056	91



# Test-Retest *Reliability* is Strong (>0.7) for all Domains Except Emotion.

EOSQ Domain	<b>Correlation Coefficient</b>
General Health	.84**
Pain/Discomfort	.85**
Pulmonary Function	.90**
Transfer	.84**
Physical Function	.97**
Daily Living	.98**
Faitgue/Energy Level	.92**
Emotion	.68*
Parental Burden	.80*
Financial Burden	.94**
Child Satisfaction	.93**
Parental Satisfation	0.89**
N = 15	$* = p < .05, ** = p \le 0.01$

### Responsiveness

Cohort	Domain	Pre-op	Post-op	P	Age Norm
	Pulmonary Function	58	98	0.083	98
	Transfer	39	61	0.045	99
SMA	Fatigue	41	52	0.078	93
	Emotion	53	69	0.080	94
	Parental Burden	40	63	0.008	93

## SMA pts show EOSQ improvements after Growing Rods/ VEPTR





## Responsiveness


Cohort	Domain	Pre-op	Post-op	P	Age Norm
Idiopathic	Physical Function	94	84	0.048	97
	Fatigue	88	69	0.076	92
	Emotion	81	60	0.006	95

Idiopathic pts, worsened in Physical Function, Fatigue, and Emotion




### **Idiopathic: Pre-Casting**

No significant difference in HRQoL compared to norms



### Non-Idiopathic: Pre-Casting

Some HRQoL significantly lower compared to norms



## Transfer, Physical Function, Emotion, and Child Satisfaction All Worsened from Pre- to Post-Casting

<b>Pre-Casting</b>	vs Post-Casting	(N = 15)

Domain Name	Mean :	Mean ± SD			
Domain Name	EOS	Norm	р		
General Health	$75 \pm 23$	$73 \pm 20$	0.700		
Pain/Discomfort	$89 \pm 18$	$86 \pm 19$	0.573		
Pulmonary Function	95 ± 11	$87 \pm 22$	0.173		
Transfer	$100 \pm 0$	$83 \pm 20$	0.007		
Physical Function	88 ± 19	$65 \pm 23$	0.010		
Daily Living	$74 \pm 33$	$57 \pm 27$	0.073		
Fatigue/Energy Level	$89 \pm 13$	$76 \pm 32$	0.170		
Emotion	97 ± 7	$88 \pm 14$	0.054		
Parental Burden	$80 \pm 21$	$72 \pm 24$	0.257		
Financial Burden	$83 \pm 20$	$72 \pm 27$	0.110		
Child Satisfaction	$90 \pm 13$	$69 \pm 29$	0.020		
Parent Satisfaction	$85 \pm 21$	$70 \pm 29$	0.108		

### Responsiveness to Clinical Change

Cohort	Domain	Pre-op	Post-op 1 <sup>st</sup> /2nd	P	Age Norm
SMA	Pulmonary Function	58	98	0.083	98
	Transfer	39	61	0.045	99
	Fatigue	41	52	0.078	93
	Emotion	53	69	0.08	94
	Parental Burden	40	63	0.008	93

**EOSQ Reflects Health Status Improvement** in SMA pts after Growing Rods



### **EOSQ** as Primary Endpoint

Do externally controlled growth rods lead to better HRQL outcomes?

Prospective study of TGR vs MAGEC with EOSQ as primary endpoint




## Conclusion: What Have We Learned from the EOSQ?

- Patients with EOS have lower QOL, even the idiopathic patients
- Intervention seems to improve QOL in nonidiopathic but worsen QOL in idiopathic
- Complications decrease QOL
- Casting Effects Qol in Children
- EOSQ is valid, relaibale and responsive and can be used as a PRO measure for EOS



### Final Thoughts: What about PROMIS?

- PROMIS: Patient-Reported Outcomes Measurement Information System.
- NIH-funded psychometric evaluation that has grown significantly over last several years: (http://www.hhs.gov/asl/testify/t051208a.html)



### PROMIS is dynamic


### **CAT:** Computer Adaptive Test

- Dynamic option: Questions are presented in <u>changing</u> sequence, with following sequence based on prior answers.
- Purpose:
  - Minimizes # questions;
  - Greater measurement precision;



### **PROMIS**

 One of the biggest advantages of the PROMIS scaled scores is that they have been adjusted so that <u>adult and pediatric scores can be</u> <u>compared directly.</u>



### **PROMIS has Infrastructure**

- Study specific instruments by choosing domains of your interest
- Assessment Center (<u>www.assessmentcenter.net</u>)
  - A free online data collection tool for PROMIS
- Patients answer questions by logging into the website
- Scaled scores are calibrated so that: (NIHpromis.org/faqs)
  - A score of **50-points** is the average score of the US population;
  - 10 -points is equal to one standard deviation.

### MORE TO COME ....





## Thank You

Michael G. Vitale, MD MPH

mgv1@columbia.edu

